Chronic Pain vs Migraine — Clinical Trial Comparison
Chronic Pain
Persistent pain lasting >3 months, multiple causes
Migraine
Severe recurrent headaches with neurological symptoms
Chronic pain and migraine are both prevalent pain conditions, but they differ significantly in their mechanisms, triggers, and treatment approaches. Chronic pain encompasses a wide range of conditions (neuropathic, musculoskeletal, fibromyalgia), while migraine is a specific neurological disorder. Their trial landscapes reflect these differences, with chronic pain trials testing broad analgesic approaches and migraine trials targeting the CGRP pathway and neurovascular mechanisms.
Key Differences at a Glance
| Feature | Chronic Pain | Migraine |
|---|---|---|
| Primary feature | Persistent pain in any body region >3 months | Recurrent severe headaches with aura possible |
| Mechanism | Varied: neuropathic, nociceptive, nociplastic | Neurovascular: trigeminovascular activation |
| Common subtypes | Neuropathic, fibromyalgia, LBP, CRPS | Episodic, chronic, vestibular, menstrual, hemiplegic |
| Severity scoring | NRS, BPI, Pain DETECT (neuropathic) | HIT-6, MIDAS, migraine days/month |
| UK prevalence | ~28% of adults experience chronic pain | ~15% of adults (migraine specifically) |
| NICE first-line | Pain management programme, CBT, exercise, analgesics | CGRP inhibitors, triptans, lifestyle modification |
Clinical Trial Availability
| Trial Aspect | Chronic Pain | Migraine |
|---|---|---|
| UK trials actively recruiting | 40–70 studies | 30–50 studies |
| Most common trial phase | Phase 2–3 | Phase 2–3 |
| Top interventions tested | Neuromodulation, cannabis-based medicines, CBT, exercise therapy | CGRP monoclonal antibodies, gepants, ditan, neuromodulation devices |
| Cannabis-based trials | Growing (especially neuropathic pain and fibromyalgia) | Limited exploratory |
| Device trials | Significant (spinal cord stimulation, TENS, peripheral nerve stimulation) | Significant (Cefaly, sTMS, vagus nerve stimulation) |
| Digital/app-based trials | Growing (pain management, CBT, activity tracking) | Growing (diary apps, trigger management) |
Exciting Emerging Treatments
Chronic Pain Trials
- Cannabis-based medicinal products — growing evidence for neuropathic and nociplastic pain
- Spinal cord stimulation advances — next-gen devices with closed-loop technology
- Psychedelic-assisted therapy — early research on psilocybin for chronic pain
- Anti-NGF antibodies — tanezumab and related compounds for osteoarthritis and LBP
- Virtual reality pain management — immersive distraction and graduated exposure
- Precision pain medicine — genetic profiling to match patients to treatments
Migraine Trials
- Next-gen CGRP inhibitors — longer-acting formulations, oral gepants for acute and prevention
- Ditans (lasmiditan) — serotonin 5-HT1F agonists without vasoconstriction
- Neuromodulation devices — external and implantable options for refractory migraine
- Anti-PACAP antibodies — new target beyond CGRP for preventive treatment
- Precision migraine medicine — genetic markers for treatment response prediction
- Calcitonin gene-related peptide vaccines — long-acting immunisation approach
💡 Pain conditions often overlap — and so do trials
Many people with migraine also experience other chronic pain conditions, and vice versa. Some trials specifically target overlapping pain syndromes. If you have both chronic pain and migraine, mention both during screening — you might qualify for trials studying central sensitisation or multi-site pain conditions.
Eligibility Differences
Chronic Pain Trial Criteria
- Pain duration > 3–6 months required (definition varies by trial)
- Average pain severity thresholds (NRS ≥ 4 or ≥ 6 typical)
- Specific pain type may be required (neuropathic vs nociceptive vs nociplastic)
- Fibromyalgia trials may use ACR criteria and tender point assessment
- Current opioid use is commonly exclusionary or requires stable dose
- Psychological screening for depression/anxiety (may be stratification factor)
Migraine Trial Criteria
- Minimum migraine frequency (typically ≥ 4 migraine days/month for prevention trials)
- Confirmed migraine diagnosis using ICHD-3 criteria
- Chronic migraine trials require ≥ 15 headache days/month (≥ 8 migraine)
- Previous preventive medication failures may be required for refractory trials
- Medication overuse headache must be ruled out or addressed
- Basilar or hemiplegic migraine may be exclusionary from some CGRP trials
🔥 Chronic Pain Trials
Find actively recruiting chronic pain clinical trials across the UK
View Chronic Pain Trials💫 Migraine Trials
Find actively recruiting migraine clinical trials across the UK
View Migraine Trials